Compare Gitlab Inc (GTLB) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Gitlab Inc trades at $53.03 (market cap $8.66B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Gitlab Inc and Kymera Therapeutics Inc. Common Stock are close in size by market cap, and Gitlab Inc is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| GTLB | KYMR | |
|---|---|---|
Market Cap | $8.66B | $8.87B |
Volume | 9,356,692 | 779,107 |
Sector | Technology | Health |
52-Week High | $56.01 | $127.31 |
52-Week Low | $19.42 | $55.80 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $7.40B | $8.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.16, down 5.09% today but remains near its 52-week high territory. The stock shows strong technical momentum with bullish moving averages despite overbought RSI readings. Fundamentally, revenue growth remains robust at 21.3% year-over-year (Q2 2026 earnings), though profitability remains elusive with negative net margins. Recent earnings beats and raised guidance have fueled positive sentiment, with the company benefiting from AI-driven demand in software development pipelines.
Outlook: GitLab's AI integration and strong execution position it for continued growth, but high valuation multiples (P/E 521) and persistent losses present risks. Analyst consensus leans Hold with $49.71 target, suggesting limited near-term upside from current levels. Key catalysts include Q3 earnings and AI product adoption, while competition and macroeconomic pressures remain headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
